Form 4: Cartesian Therapeutics Director Timothy Springer Increases Stake in Company

Director Timothy Springer reports purchasing additional shares of Cartesian Therapeutics (RNAC) on March 14 and 15, 2024.

Summary

• On March 14, 2024, Timothy Springer, a director and 10% owner of Cartesian Therapeutics, acquired 648,372 shares of common stock at a weighted average price of $0.5424 per share.
• These purchases were made in multiple transactions with prices ranging from $0.5002 to $0.5600.
• Following this transaction, Springer indirectly beneficially owned 30,516,862 shares through TAS Partners LLC, where he is the managing member.
• On March 15, 2024, Springer acquired an additional 537,500 shares at a weighted average price of $0.5852 per share, with prices ranging from $0.5326 to $0.60.
• After this second purchase, Springer indirectly beneficially owned 31,054,362 shares through TAS Partners LLC.
• Springer also directly owns 7,471,625 shares and indirectly owns 86,418 shares through his wife.

Sentiment

Score: 7

Explanation: Insider buying is generally viewed positively, suggesting confidence in the company's future. However, it's just one data point and needs to be considered alongside other factors.

Positives

• A director increasing their stake in the company can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored as an indicator of management's confidence in the company's prospects. It's a common practice and is regulated to prevent illegal activities.

Stakeholder Impact

• The increased stake by a director could positively influence shareholder sentiment.

Key Dates